Controlled Trial of 3 4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS)
Robert Pascuzzi, MD
Primary Investigator
Overview
The overall purpose is to provide children access to 3,4-DAP, which is not currently approved by the FDA for use in the United States.
Description
This study is designed to provide 3,4-DAP to patients with Lambert-Eaton Myasthenic Syndrome (LEMS) in attempt to improve their quality of life.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Lambert-Eaton Myasthenic Syndrome (LEMS),Lambert-Eaton Myastenic Syndrome
-
Age: Between 4 Years - 100 Years
-
Gender: All
Inclusion Criteria
Diagnosed with Lambert-Eaton Myasthenic Syndrome
If female, have a negative pregnancy test and, if premenopausal, be willing to practice and effective form of birth control during this treatment
Exclusion Criteria
Known sensitivity to 3,4-DAP
Has a history of past or current seizures or of severe asthma
Is believed by the investigator to be unable to comply with the protocol